

Sardesai Niranjan  
Form 3  
January 04, 2012

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Sardesai Niranjan		(Month/Day/Year)	INOVIO PHARMACEUTICALS, INC. [INO]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		01/03/2012		
11494 SORRENTO VALLEY ROAD,Â SUITE A			(Check all applicable)	
(Street)			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
SAN DIEGO,Â CAÂ 92121			(give title below)	(specify below)
(City)	(State)	(Zip)	Chief Operating Officer	
				6. Individual or Joint/Group Filing(Check Applicable Line)
				<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	66,800	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	--	--	---

Edgar Filing: Sardesai Niranjn - Form 3

	Date Exercisable	Expiration Date	Amount or Number of Shares			or Indirect (I) (Instr. 5)	
<u>Common Stock Option (1)</u>	08/28/2006	08/28/2016	Common Stock 132,462	\$ 1.53		D	Â
<u>Common Stock Option (1)</u>	01/05/2007	01/05/2017	Common Stock 24,530	\$ 1.53		D	Â
<u>Common Stock Option (1)</u>	01/18/2007	01/18/2017	Common Stock 14,718	\$ 1.53		D	Â
<u>Common Stock Option (1)</u>	11/01/2007	11/01/2017	Common Stock 73,590	\$ 1.53		D	Â
<u>Common Stock Option (1)</u>	09/12/2008	09/12/2018	Common Stock 29,436	\$ 1.53		D	Â
<u>Common Stock Option (1)</u>	09/12/2008	09/12/2018	Common Stock 19,624	\$ 1.53		D	Â
<u>Common Stock Option (2)</u>	09/30/2009	09/30/2019	Common Stock 120,000	\$ 1.57		D	Â
<u>Common Stock Option (3)</u>	03/11/2011	03/11/2021	Common Stock 120,000	\$ 1.14		D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sardesai Niranjn 11494 SORRENTO VALLEY ROAD SUITE A SAN DIEGO, CA 92121	Â	Â	Â Chief Operating Officer	Â

## Signatures

/s/ Niranjn Sardesai 01/04/2012

\*\*Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Issued upon assumption of outstanding VGX Pharmaceutical Inc. stock options in conjunction with closing of the business combination transaction between VGX Pharmaceuticals and Inovio Pharmaceuticals, Inc. on June 1, 2009. As of January 4, 2012, options are fully vested and exercisable.
- (1) The vesting schedule for the 120,000 options is as follows: 30,000 shares vested on September 30, 2009; 30,000 shares vested on September 30, 2010; 30,000 shares vested on September 30, 2011; 30,000 shares will vest on September 30, 2012.
  - (2) The vesting schedule for the 120,000 options is as follows: 30,000 shares vested on March 11, 2011; 30,000 shares will vest on March 11, 2012; 30,000 shares will vest on March 11, 2013; 30,000 shares will vest on March 11, 2014
  - (3)

## Edgar Filing: Sardesai Niranjan - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.